ESMO Virtual Journal Club: December 2024

This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Programme

• 4 December 2024

Welcome and introduction

Pilar Garrido

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Mariana Brandao

RUBY Trial in Endometrial Cancer. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Domenica Lorusso

Live Q&A and Discussion

All speakers

• 

  Pilar Garrido

  Chair

  University Hospital Ramón y Cajal (IRYCIS)
  Madrid
• 

  Mariana Brandão

  Speaker

  Institut Jules Bordet
  Brussels
• 

  Domenica Lorusso

  Speaker

  Humanitas Hospital San Pio X
  Humanitas University, Rozzano
  Milan

Description

This ESMO Virtual Journal Club Webinar focused on two newly published studies, with an aim to enhance understanding and application of the latest research in the field.

This webinar aimed to discuss and evaluate notable recent publications on the topics of non-small-cell lung cancer, as well as new treatments in endometrial cancers.

Shun Lu, Terufumi Kato, Xiaorong Dong et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine.
DOI: 10.1056/NEJMoa2402614

M.A. Powell, L. Bjørge, L. Willmott et al. RUBY Trial in Endometrial Cancer. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Annals of Oncology.
DOI: 10.1016/j.annonc.2024.05.546

Learning objectives

• To discuss and critically evaluate notable recent publications.
• To enhance the understanding and application of the latest research in the field.
• To assess the study’s robustness, its significance to oncology practice, limitations, and its place within existing research.
• To identify and highlight any unclear aspects or unmet needs.